SPSebnem Pehlivanoglu

Sebnem Pehlivanoglu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sebnem Pehlivanoglu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Nephroprotective and therapeutic potential of Helichrysum orientale (L.) Gaertn. on hydrogen peroxide-injured kidney cells

    by Suray Pehlivanoglu, Cigdem Aydin Acar, Sebnem Pehlivanoglu, Sukriye Yesilot, Hatice Ceylan

    Acute kidney injury (AKI) is a severe form of kidney disease that is characterized by dysfunction. Excessive production of reactive oxygen species (ROS) is a major contributing factor in AKI pathogenesis. This study aims to investigate the cytoprotective effects of Helichrysum orientale (L.) Gaertn.'s capitulum aqueous extract against hydrogen peroxide (H₂O₂)-induced oxidative stress and apoptosis of 293 T cells (in vitro AKI model). The polyphenolic content of the extract was determined using ultra-high-performance liquid chromatography (UHPLC) revealing substantial amounts of cinnamic acid derivatives as well as notable quantities of polyphenolic compounds. Cell viability assays demonstrated that H₂O₂ induced dose-dependent cytotoxicity, whereas the extract significantly mitigated these effects and increased cell viability up to 2.43-fold. The antioxidant activities of the extract were evidenced by 5.1-fold increase in catalase (CAT) activity, 3.3-fold increase in superoxide dismutase (SOD) activity, and 2.3-fold reduction in malondialdehyde (MDA) levels. These results indicate its capacity to counteract H₂O₂-induced oxidative damage. Additionally, the extract prevented apoptotic cell death by significantly downregulating Bax expression by 16% and suppressing caspase-3 activation to control levels in damaged cells. These findings demonstrate that the aqueous extract of H. orientale's capitulum exhibits robust antioxidant and antiapoptotic properties in H₂O₂-injured kidney cells, offering preliminary pre-clinical substantiation.


  • Open Access

    Changes in Phosphorylation Levels of PKA, AKT(PKB) and PKC Targeted AKT Substrates Upon EGF Stimulation in Metastatic Breast Cancer Cells

    by Merve Özcan Türkmen, Şebnem Pehlivanoğlu

    Protein kinaz B (PKB/AKT), hücre metabolizması, büyüme, çoğalma ve tümör invazyonu dahil olmak üzere çok çeşitli fizyolojik ve patolojik süreçleri düzenleyen fosfatidilinositol-3-kinaz (PI3K)/AKT sinyal yolağının temel düzenleyicisidir. AKT enzimi, EGF gibi hücresel uyarıcı moleküller tarafından aktive edilebilen bir serin/treonin kinazdır. Aktive AKT enzimi, hedef substratlarını RxRxxS/T konsensus dizisine bağlanarak fosforile eder. Bazı AKT hedefleri, farklı serin/treonin kinazlar tarafından benzer rezidulardan fosforile edilebilmektedir. Bu substratlar üzerinde yapılan birçok çalışma, sinyal yolakları arası etkileşimi sağlayan ortak moleküllerin ve yeni terapötik hedeflerin belirlenmesi için değerli bilgiler sunmaktadır. Bu bağlamda söz konusu çalışmada, EGF uyarımına bağlı olarak MDA-MB-231 üçlü negatif metastatik meme kanseri hücrelerinde, AKT substrat fosforilasyonlarını mimik eden PKA, PKB(AKT) ve PKC hedefli yeni moleküllerin belirlenmesi amaçlanmıştır. AKT substratlarının fosforilasyon düzeyleri Western blot analizi ile değerlendirildi. Elde edilen sonuçlara göre, PKA, PKB ve PKC inhibitörlerinin varlığında ve EGF uyarımı ile birlikte 30 kDa ağırlığında bir fosfo-proteininin (pp30), AKT substrat fosforilasyon düzeyinin değiştiği saptandı. EGF uyarımına bağlı olarak, beklendiği üzere AKT substratlarının fosforilasyon düzeyleri artarken, inhibitörler bu fosforilasyonları baskılamaktadır. Dikkat çekici bir şekilde, PKC inhibitörü varlığında pp30’un fosforilasyon düzeyinin, EGF uyarımına rağmen kontrole kıyasla azaldığı belirlendi. Bu sonuç, pp30’un hücresel regülasyonunun PKC tarafından AKT ile aynı bölgeden gerçekleşebileceğini ortaya koymaktadır. Çalışmamızdaki metodoloji, AKT ile PKC sinyal yolakları arasındaki etkileşimde rolü olabilecek yeni potansiyel düzenleyicilerin tanımlanabilmesinin mümkün olduğunu göstermektedir. Ancak, bu etkileşimin ne yönde olduğunu açıklayabilmek için ileri çalışmalara ihtiyaç vardır

  • Craniosynostosis: Clinical Characteristics, Molecular Mechanisms and Treatment

    by Sebnem Pehlivanoglu

    Craniosynostosis is a congenital condition marked by the early fusion of one or more cranial sutures. Cranial sutures are fibrous tissues that connect the skull bones. They play a crucial role in ensuring bone formation at the edges of the calvarial bones, which move apart to facilitate the passage of the head through the birth canal and allow for future brain growth. The premature fusion limits skull growth perpendicular to the affected sutures, potentially resulting in abnormal head shapes, increased intracranial pressure, and developmental delays. The prevalence of craniosynostosis is about 1 in 2100-3000 births. Craniosynostosis is primarily categorized into primary and secondary types. Primary craniosynostosis is further divided into non-syndromic and compound craniosynostosis, the latter including bicoronal synostosis and syndromic craniosynostosis. Approximately 85% of craniosynostosis cases are non-syndromic, with 92% being sporadic. Non-syndromic craniosynostosis can present as sagittal, coronal, metopic, or lambdoid synostosis. Sagittal synostosis is the most common type, with a prevalence of 40–55%. To date, over 180 craniosynostotic syndromes have been described. Typically, these syndromes show autosomal, recessive, and X-linked inheritance patterns. Some classic craniosynostosis syndromes include Apert syndrome, Antley-Bixler syndrome, Carpenter syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Muenke syndrome, Pfeiffer syndrome, and Saethre-Chotzen syndrome. The genes associated with craniosynostoses include FGFR1, FGFR2, FGFR3, TWIST1, RAB23, EFNB1, TCF12, MSX2, POR, and ERF. FGFR signaling regulates proteoblast/osteoblast differentiation, proliferation, migration, and apoptosis, as well as vertebrate organogenesis and morphogenesis. Gain-of-function mutations in components of this signaling pathway have been implicated in craniosynostoses. Genetic algorithms provide a roadmap for diagnosing syndromic craniosynostosis based on genetic causes. Genetic tests should be guided by clinical findings, family history, and available scientific evidence. The diagnosis of a specific type of syndromic craniosynostosis should integrate clinical and genetic findings. Managing craniosynostosis requires a collaborative effort from various medical disciplines. Treatment typically involves surgical intervention to address both functional and cosmetic concerns. The optimal timing and approach to treatment depend on factors such as the severity of cranial deformity, the age of the patient, and the specific type of craniosynostosis.